Hemophagocytic lymphohistiocytosis associated with dabrafenib and trametinib combination therapy following pembrolizumab administration for advanced melanoma

Ann Oncol. 2018 Jul 1;29(7):1602-1603. doi: 10.1093/annonc/mdy175.

Authors

K Sasaki¹, J Uehara², S Iinuma², H Doi², M Honma², Y Toki³, A Ishida-Yamamoto²

Affiliations

¹ Department of Dermatology, Asahikawa Medical University, Asahikawa, Hokkaido, Japan. Electronic address: kentas-canon@asahikawa-med.ac.jp.
² Department of Dermatology, Asahikawa Medical University, Asahikawa, Hokkaido, Japan.
³ Division of Gastroenterology and Hematology/Oncology, Department of Medicine, Asahikawa Medical University, Asahikawa, Hokkaido, Japan.

PMID: 29741568
DOI: 10.1093/annonc/mdy175

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Antibodies, Monoclonal, Humanized / administration & dosage
Antineoplastic Combined Chemotherapy Protocols / adverse effects*
Female
Humans
Imidazoles / administration & dosage
Lung Neoplasms / drug therapy*
Lung Neoplasms / secondary
Lymphohistiocytosis, Hemophagocytic / chemically induced*
Lymphohistiocytosis, Hemophagocytic / drug therapy
Melanoma / drug therapy*
Melanoma / pathology
Middle Aged
Oximes / administration & dosage
Prognosis
Pyridones / administration & dosage
Pyrimidinones / administration & dosage

Substances

Antibodies, Monoclonal, Humanized
Imidazoles
Oximes
Pyridones
Pyrimidinones
trametinib
pembrolizumab
dabrafenib